Cancer
Malignant Nasopharyngeal Neoplasm
CI-CAN-00005902Explore in graph →
Top-level261 active trials1 approved drugs
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005902Explore in graph →
Clinical trials
771 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (43)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00941538 | Cluster Randomized Controlled Screening Trial for NPC(CRCSTNPC) | unknown | N/A | 87,600 | Sun Yat-sen UniversityOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT04872582 | Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study | unknown | Phase 2 | 33 | XIANG YANQUNOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT04945421 | IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC | completed | Phase 1 | 30 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Feb 23, 2023 | clinicaltrials |
| NCT04813705 | 18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 93 | Taizhou HospitalOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05724355 | CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC | unknown | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05549466 | Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC | unknown | Phase 2 | 84 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05717764 | Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment | not yet recruiting | Phase 3 | 500 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.INDUSTRY | 0 | Feb 8, 2023 | clinicaltrials |
| NCT05717790 | Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma | recruiting | N/A | 288 | Fourth Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04405622 | Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. | unknown | Phase 2 | 21 | Sun Yat-sen UniversityOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05707819 | Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma | recruiting | — | 43 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT04350190 | Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 25 | Wei JiangOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT05682703 | A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma. | unknown | — | 2,000 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT05674305 | Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy | recruiting | Phase 3 | 366 | Fudan UniversityOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05654077 | EBV CAR-T Cells for Nasopharyngeal Carcinoma | unknown | Early Phase 1 | 24 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT05616468 | BGT007 Cell Treatment of Nasopharyngeal Carcinoma | unknown | Early Phase 1 | 23 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05652192 | SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC | recruiting | Phase 2 | 37 | Zhejiang Cancer HospitalOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT05628922 | Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT | recruiting | Phase 2 | 198 | Fudan UniversityOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05627310 | Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic Images | unknown | — | 50,000 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT05622474 | A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy | not yet recruiting | N/A | 236 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2022 | clinicaltrials |
| NCT05415098 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | unknown | Phase 1 | 90 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Nov 16, 2022 | clinicaltrials |
| NCT03837808 | Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma | unknown | Phase 3 | 384 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT04636632 | Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma | completed | Phase 1 | 100 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT02460419 | Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma | completed | Phase 3 | 104 | Sun Yat-sen UniversityOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT00274937 | Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer | completed | Phase 3 | 111 | Children's Oncology GroupNETWORK | 3 | Oct 25, 2022 | clinicaltrials |
| NCT00188253 | Positron Emission Tomography Scanning and Epstein-Barr Virus DNA Levels in the Staging and Follow-up of Nasopharyngeal Carcinoma. | completed | — | 30 | University Health Network, TorontoOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT02063399 | Prospective Nasopharyngeal Carcinoma Screening Using Plasma Epstein-Barr Virus DNA Analysis | unknown | — | 20,302 | Chinese University of Hong KongOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT05547971 | Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics | unknown | — | 800 | Xiangya Hospital of Central South UniversityOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT05519956 | Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines | unknown | Phase 3 | 398 | Fujian Cancer HospitalOTHER_GOV | 0 | Sep 19, 2022 | clinicaltrials |
| NCT03448341 | Dysphagia Assessment After Swallowing Sparing RadioTherapy(DASRT) | completed | — | 74 | Azienda Ospedaliero, Universitaria PisanaOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05514275 | Radiotherapy Combined With Endostatin and Capecitabine for NPC | recruiting | Phase 2 | 41 | Zhejiang Cancer HospitalOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT04898374 | Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma | unknown | Phase 3 | 120 | Kuwait Cancer Control CenterOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05503914 | Low-dose Radiotherapy and Neoadjuvant Chemotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma | unknown | N/A | 80 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05397769 | Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial. | recruiting | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT05484375 | Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment | not yet recruiting | Phase 2 | 40 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 0 | Aug 2, 2022 | clinicaltrials |
| NCT00470496 | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer | completed | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT03121716 | A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects | completed | Phase 1 | 23 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05447169 | Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening | recruiting | — | 11,625 | Sun Yat-sen UniversityOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT05448885 | Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma | unknown | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT04398056 | Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 22 | Sun Yat-sen UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05037357 | Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements | unknown | — | 370 | Sun Yat-sen UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT03707509 | Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 3 | 263 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05352321 | Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma | recruiting | N/A | 264 | Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05432219 | A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma | unknown | N/A | 20 | Eye & ENT Hospital of Fudan UniversityOTHER | 0 | Jun 27, 2022 | clinicaltrials |
| NCT05433597 | A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC | not yet recruiting | Phase 2 / Phase 3 | 172 | Sun Yat-sen UniversityOTHER | 0 | Jun 27, 2022 | clinicaltrials |
| NCT05431764 | Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 38 | Sun Yat-sen UniversityOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05417139 | Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study | unknown | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04978012 | Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy | unknown | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT04437329 | Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 352 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 28, 2023source: clinicaltrials